#1 Clinical Trials Search in Europe

Cefazolin

Cefazolin, a first-generation cephalosporin antibiotic, is being studied in various clinical trials to evaluate its effectiveness in different medical situations. These trials aim to determine optimal dosing, tissue concentrations, and efficacy in preventing infections across diverse patient populations, including those undergoing bariatric surgery, cesarean delivery, and other procedures. The research also explores cefazolin’s use in special circumstances such as continuous renal replacement therapy and its application in neonatal care.

Table of Contents

What is Cefazolin?

Cefazolin, also known by brand names such as Ancef, Kefzol, or Cefamezine, is an antibiotic medication belonging to the cephalosporin class of drugs[1][2]. It is widely used in medical practice, particularly for preventing and treating various types of bacterial infections.

Uses of Cefazolin

Cefazolin is primarily used for the following purposes:

  • Surgical Prophylaxis: It is commonly administered before surgery to prevent infections. This includes various types of surgeries such as:
    • Bariatric surgery (weight loss surgery)[3]
    • Cesarean sections (C-sections)[2]
    • Orthopedic procedures, including joint replacements[4]
  • Treatment of Active Infections: Cefazolin can be used to treat various bacterial infections, including:
    • Skin and soft tissue infections
    • Bone and joint infections
    • Respiratory tract infections
  • Prevention of Postpartum Infections: It may be used to prevent infections in women after childbirth, especially following perineal tears during vaginal delivery[5]

How Cefazolin Works

Cefazolin is an antibiotic that works by interfering with the cell wall synthesis of bacteria. This action prevents bacteria from growing and multiplying, ultimately leading to their death. It is effective against many types of bacteria, particularly those that commonly cause surgical site infections and other healthcare-associated infections[3].

Administration and Dosage

Cefazolin is typically administered in the following ways:

  • Intravenous (IV) Injection: Most commonly, cefazolin is given through an IV line directly into the bloodstream. This is especially true for surgical prophylaxis, where it’s usually given 30-60 minutes before the incision is made[3].
  • Dosage: The dosage can vary depending on the patient’s weight, kidney function, and the specific medical condition being treated or prevented. Common dosages include:
    • 2 grams for average-weight adults[6]
    • 3 grams for individuals weighing 120 kg or more[7]
    • 4 grams in some cases, especially for obese patients undergoing certain surgeries[2]

Research and Clinical Trials

Ongoing research aims to optimize the use of cefazolin in various clinical scenarios:

  • Obesity and Dosing: Studies are investigating whether higher doses of cefazolin are needed for obese patients to achieve adequate antibiotic levels in their tissues[8].
  • Extended Prophylaxis: Research is comparing the effectiveness of a single dose versus multiple doses of cefazolin in preventing infections after certain surgeries, such as joint replacement revisions[4].
  • Special Populations: Studies are examining the use of cefazolin in specific groups, such as neonates (newborns) and patients undergoing continuous renal replacement therapy (a type of dialysis)[9][10].

Safety and Side Effects

Cefazolin is generally considered safe and well-tolerated. However, like all medications, it can cause side effects in some people. Common side effects may include:

  • Nausea or vomiting
  • Diarrhea
  • Skin rash or itching
  • Pain or inflammation at the injection site

Serious allergic reactions are rare but can occur. Patients with a known allergy to penicillins or other cephalosporins should inform their healthcare provider before receiving cefazolin[9].

It’s important to note that while cefazolin is effective against many bacteria, its overuse or misuse can contribute to antibiotic resistance. Therefore, it should only be used as prescribed by a healthcare professional[4].

Aspect Details
Main Uses in Trials Antibiotic prophylaxis in surgeries, infection prevention in various patient groups
Administration Methods Intravenous injection, continuous infusion, mixed in CRRT solutions
Patient Populations Obese patients, neonates, surgical patients (bariatric, cesarean, etc.)
Key Research Areas Optimal dosing, tissue concentrations, efficacy in preventing infections
Special Considerations Dosing adjustments for obesity, use in continuous renal replacement therapy
Safety Monitoring Adverse events, allergic reactions, kidney function changes
Outcome Measures Serum and tissue drug levels, infection rates, pharmacokinetic parameters

FAQ

  • What is cefazolin used for in clinical trials? Cefazolin is being studied for various uses, including antibiotic prophylaxis in surgeries like bariatric procedures and cesarean deliveries, treatment of fingertip amputations, and prevention of infections in different patient groups.
  • How is cefazolin administered in these trials? Cefazolin is typically administered intravenously. The dosage and timing vary depending on the study, but it's often given before surgery as a preventive measure. Some trials are exploring continuous infusion methods or mixing cefazolin into renal replacement therapy solutions.
  • Are there special considerations for cefazolin use in obese patients? Yes, several trials are specifically looking at cefazolin dosing in obese and morbidly obese patients. These studies aim to determine if higher doses are needed to achieve adequate antibiotic levels in adipose tissue and blood.
  • Is cefazolin being studied in children or newborns? Yes, there is a trial investigating cefazolin pharmacokinetics in neonates to optimize dosing regimens for this age group. This research is important for understanding how newborns process and eliminate the drug.
  • What are some potential side effects of cefazolin being monitored in these trials? While specific side effects vary by study, researchers are generally monitoring for adverse events related to cefazolin use. This may include allergic reactions, changes in kidney function, and local reactions at the injection site. The overall safety profile of cefazolin is being assessed in different patient populations.

Ongoing Clinical Trials on Cefazolin

  • Study on Antibiotic Levels in Blood of Pregnant Women with Twins Using Piperacillin, Tazobactam, Cefazolin, Ampicillin Sodium, and Clindamycin

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria

  • Study on How Albumin Levels Affect Cefazolin in Heart Disease Patients with Low Albumin Undergoing Cardiac Surgery

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria

  • Study on Antibiotic Prophylaxis with Piperacillin, Tazobactam, and Cefazolin for Burn Patients Undergoing Excision-Graft Surgery

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Treating Acute Osteomyelitis in Children with Amoxicillin and Cloxacillin Compared to Standard Hospital Care

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Study of the distribution of cefazolin in the chest area of children undergoing heart surgery to prevent infection.

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Necessity of Cefazolin in Preventing Infections After Inguinal or Femoral Hernia Surgery

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on How Antibiotics Work in the Spinal Fluid of Children with Brain Drains: Cefuroxime, Vancomycin, and Gentamicin with a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria

  • Study of Cefazolin for Patients on Chronic Hemodialysis with Infections

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Cefazolin: A first-generation cephalosporin antibiotic used to prevent and treat various bacterial infections.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and elimination.
  • Antibiotic prophylaxis: The use of antibiotics to prevent infections, often given before surgery or medical procedures.
  • Body Mass Index (BMI): A measure that uses your height and weight to work out if your weight is healthy, calculated by dividing weight in kilograms by height in meters squared.
  • Cesarean delivery: A surgical procedure used to deliver a baby through incisions in the mother's abdomen and uterus.
  • Continuous Renal Replacement Therapy (CRRT): A type of dialysis treatment for patients with acute kidney injury, providing continuous blood filtration and cleansing.
  • Minimal Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Adipose tissue: Body fat, or fatty tissue, used to store energy in the form of lipids.
  • Perineal tear: A laceration of the skin and muscles between the vaginal opening and the anus that can occur during childbirth.
  • Surgical site infection (SSI): An infection that occurs after surgery in the part of the body where the surgery took place.

References

  1. https://clinicaltrials.gov/study/NCT02077400
  2. https://clinicaltrials.gov/study/NCT01755026
  3. https://clinicaltrials.gov/study/NCT01537380
  4. https://clinicaltrials.gov/study/NCT06402591
  5. https://clinicaltrials.gov/study/NCT04763486
  6. https://clinicaltrials.gov/study/NCT01880112
  7. https://clinicaltrials.gov/study/NCT05309304
  8. https://clinicaltrials.gov/study/NCT02049944
  9. https://clinicaltrials.gov/study/NCT01295606
  10. https://clinicaltrials.gov/study/NCT03672149